{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-107249","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.771948+00:00","generated_at":"2026-05-16T23:59:21.775907+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate","bullets":["100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.","All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.","DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.","EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-107249","json":"https://secwatch.observer/filing/0001213900-25-107249.json","markdown":"https://secwatch.observer/filing/0001213900-25-107249.md","text":"https://secwatch.observer/filing/0001213900-25-107249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/0001213900-25-107249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/ea0264099-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:59:21.775907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}